Literature DB >> 14742716

Association with membrane protrusions makes ErbB2 an internalization-resistant receptor.

Anette M Hommelgaard1, Mads Lerdrup, Bo van Deurs.   

Abstract

In contrast to the epidermal growth factor (EGF) receptor, ErbB2 is known to remain at the plasma membrane after ligand binding and dimerization. However, why ErbB2 is not efficiently down-regulated has remained elusive. Basically, two possibilities exist: ErbB2 is internalization resistant or it is efficiently recycled after internalization. By a combination of confocal microscopy, immunogold labeling electron microscopy, and biochemical techniques we show that ErbB2 is preferentially associated with membrane protrusions. Moreover, it is efficiently excluded from clathrin-coated pits and is not seen in transferrin receptor-containing endosomes. This pattern is not changed after binding of EGF, heregulin, or herceptin. The exclusion from coated pits is so pronounced that it cannot just be explained by lack of an internalization signal. Although ErbB2 is a raft-associated protein, the localization of ErbB2 to protrusions is not a result of raft binding. Also, an intact actin cytoskeleton is not required for keeping ErbB2 away from coated pits. However, after efficient cross-linking, ErbB2 is removed from protrusions to occur on the bulk membrane, in coated pits, and in endosomes. These data show that ErbB2 is a remarkably internalization-resistant receptor and suggest that the mechanism underlying the firm association of ErbB2 with protrusions also is the reason for this resistance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742716      PMCID: PMC379255          DOI: 10.1091/mbc.e03-08-0596

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  49 in total

1.  Molecular requirements for the effect of neuregulin on cell spreading, motility and colony organization.

Authors:  A Chausovsky; H Waterman; M Elbaum; Y Yarden; B Geiger; A D Bershadsky
Journal:  Oncogene       Date:  2000-02-17       Impact factor: 9.867

Review 2.  Structure and function of sphingolipid- and cholesterol-rich membrane rafts.

Authors:  D A Brown; E London
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

3.  c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells.

Authors:  B H Brandt; A Roetger; T Dittmar; G Nikolai; M Seeling; A Merschjann; J R Nofer; G Dehmer-Möller; R Junker; G Assmann; K S Zaenker
Journal:  FASEB J       Date:  1999-11       Impact factor: 5.191

4.  Heregulin-dependent translocation and hyperphosphorylation of ErbB-2.

Authors:  W Zhou; G Carpenter
Journal:  Oncogene       Date:  2001-06-28       Impact factor: 9.867

Review 5.  Lipid rafts and signal transduction.

Authors:  K Simons; D Toomre
Journal:  Nat Rev Mol Cell Biol       Date:  2000-10       Impact factor: 94.444

6.  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

Authors:  M A Molina; J Codony-Servat; J Albanell; F Rojo; J Arribas; J Baselga
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

Review 7.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

Review 8.  The basic biology of HER2.

Authors:  I Rubin; Y Yarden
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

9.  Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2.

Authors:  L N Klapper; H Waterman; M Sela; Y Yarden
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

Review 10.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.

Authors:  Antony W Burgess; Hyun-Soo Cho; Charles Eigenbrot; Kathryn M Ferguson; Thomas P J Garrett; Daniel J Leahy; Mark A Lemmon; Mark X Sliwkowski; Colin W Ward; Shigeyuki Yokoyama
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

View more
  78 in total

1.  In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas.

Authors:  Susan L Deutscher; Said D Figueroa; Senthil R Kumar
Journal:  J Labelled Comp Radiopharm       Date:  2009-12-01       Impact factor: 1.921

2.  Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus.

Authors:  Mads Lerdrup; Silas Bruun; Michael V Grandal; Kirstine Roepstorff; Malene M Kristensen; Anette M Hommelgaard; Bo van Deurs
Journal:  Mol Biol Cell       Date:  2007-07-11       Impact factor: 4.138

3.  The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane.

Authors:  Camilla Haslekås; Kamilla Breen; Ketil W Pedersen; Lene E Johannessen; Espen Stang; Inger Helene Madshus
Journal:  Mol Biol Cell       Date:  2005-10-05       Impact factor: 4.138

4.  The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR.

Authors:  Xiangdong Zhou; Yehenew M Agazie
Journal:  Cell Signal       Date:  2011-09-03       Impact factor: 4.315

5.  Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.

Authors:  L Alexis Hoeferlin; Charles E Chalfant; Margaret A Park
Journal:  J Surg Sci       Date:  2013-12

6.  Resistance to Trastuzumab in Breast Cancer.

Authors:  Paula R Pohlmann; Ingrid A Mayer; Ray Mernaugh
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

7.  Interactions between anti-ErbB2 antibody A21 and the ErbB2 extracellular domain provide a basis for improving A21 affinity.

Authors:  Liang Chang; Changhai Zhou; Man Xu; Jing Liu
Journal:  J Comput Aided Mol Des       Date:  2009-12-12       Impact factor: 3.686

8.  Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.

Authors:  Cary D Austin; Ann M De Mazière; Paul I Pisacane; Suzanne M van Dijk; Charles Eigenbrot; Mark X Sliwkowski; Judith Klumperman; Richard H Scheller
Journal:  Mol Biol Cell       Date:  2004-09-22       Impact factor: 4.138

9.  Aberrant endocytosis leads to the loss of normal mitotic spindle orientation during epithelial glandular morphogenesis.

Authors:  James W Clancy; Colin S Sheehan; Christopher J Tricarico; Crislyn D'Souza-Schorey
Journal:  J Biol Chem       Date:  2018-06-14       Impact factor: 5.157

10.  Caveolin-1 induces formation of membrane tubules that sense actomyosin tension and are inhibited by polymerase I and transcript release factor/cavin-1.

Authors:  Prakhar Verma; Anne G Ostermeyer-Fay; Deborah A Brown
Journal:  Mol Biol Cell       Date:  2010-04-28       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.